AcuraStem
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 N Orange Grove Blvd Ste 220, Pasaden...Phone Number
(213) 290-0635Website
www.acurastem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About AcuraStem
AcuraStem's team of PhDs, professors, tech entrepreneurs, and successful drug company veterans are employing the latest scientific breakthroughs to address the most challenging, but we believe tractable, health problems of our time, including amyotrophic lateral sclerosis (ALS). Our best-in-class technology platform consists of complex cellular models from ALS patient cells and sophisticated assays which permit AcuraStem's scientists to model patient tissues in the laboratory. Using this ground-breaking technology, we can screen small molecule or gene targeting libraries to discover the most efficacious therapeutic opportunities. AcuraStem's iNeuroRx® platform is a breakthrough disease modeling platform, leveraging neurons derived from patients and advanced machine learning to discover therapeutic opportunities that rescue healthy motor neurons in those affected by neurodegenerative diseases, like ALS and FTD (frontotemporal dementia). AcuraStem has found unique therapeutic targets thaRead more
AcuraStem Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AcuraStem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AcuraStem has new funding data
Check if AcuraStem has recently received funding, and reach out quickly before it becomes old news!
AcuraStem, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at AcuraStem
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AcuraStem launches new products
Check out if AcuraStem is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if AcuraStem had a recent Job posting/layoffs
Earning: See what the market has to say on AcuraStem recently announced quarterly report
Recommended Actions
Find VP level buyers at AcuraStem
Find 2 more new buyers
Compare Similar Companies to AcuraStem
Compare insights from companies similar to AcuraStem, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Company Profile Activity
Activity Insights
AcuraStem is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AcuraStem is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AcuraStem.
AcuraStem financials insights
Gather financial insights about AcuraStem, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Grant
$7M
AcuraStem Tech Stack
A closer look at the technologies used by AcuraStem
See more technologies
Most Recent Scoops
Open Position
Open Position
Project
, according to a mid-level source in Operations Management, is in the midst of initiatives related to document generation software. AcuraStem is currently evaluating Overleaf.
Document Management, Software, Operations
Project
, according to a mid-level source in Operations Management, is in the midst of initiatives related to quality management. AcuraStem is currently evaluating Compass by Creato.
Quality Management, Operations
Project
Data Management, Data Warehousing, Accessibility, Operations
AcuraStem News & Media
CIRM Awards AcuraStem $7.5 Million in Grant Funding to Advance AS-241 Toward a First-in-Human Trial for ALS and FTD
PASADENA, Calif., April 28, 2026 /PRNewswire/ -- AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine...AcuraStem Awarded Target ALS Grant to Advance Therapeutics Targeting a Core Driver of ALS
PASADENA, Calif., March 10, 2026 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ALS to advance therapeutics targeting...AcuraStem Secures $4 Million in Grant Funding from CIRM to Advance UNC13A Program for ALS and FTD
PASADENA, Calif., Sept. 3, 2024 /PRNewswire/ -- AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has successfully secured $4 million...AcuraStem Secures $7M in Grant
AcuraStem, a Pasadena, CA-based patient-based biotechnology company advancing treatments for neurodegenerative diseases, received a $7M Grant. The National Institutes of... Read More The post AcuraStem Secures $7M in Grant appeared first on citybiz.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding AcuraStem
Sign Up For FreeTo access detailed company insights
AcuraStem's team of PhDs, professors, tech entrepreneurs, and successful drug company veterans are employing the latest scientific breakthroughs to address the most challenging, but we believe tractable, health problems of our time, including amyotrophic lateral sclerosis (ALS). Our best-in-class technology platform consists of complex cellular mod... Read More
